
First published in the Government *Gazette*, Electronic Edition, on 23 April 2021 at 8.15 pm.

No. S 273

INFECTIOUS DISEASES ACT
(CHAPTER 137)

INFECTIOUS DISEASES (COVID-19 CLEARANCE)
REGULATIONS 2021

ARRANGEMENT OF REGULATIONS

PART 1

PRELIMINARY

Regulation

1. Citation and commencement
2. General definitions
3. *[Deleted]*
4. Digital certificates and automated decision making, etc.
5. *[Deleted]*

PART 2

CLEARED STATUS AND NEGATIVE RESULTS

6. Meaning of “cleared status (general)”
7. *[Deleted]*
- 7A. Meaning of “cleared status (special)”
- 7B. *[Deleted]*
8. What is negative test result
- 8A. When is cleared status current

PART 3

[REPEALED]

The Schedules

In exercise of the powers conferred by section 73(1) of the Infectious Diseases Act, the Minister for Health makes the following Regulations:

PART 1
PRELIMINARY

Citation and commencement

1. These Regulations are the Infectious Diseases (COVID-19 Clearance) Regulations 2021 and come into operation on 24 April 2021.

[S 991/2021 wef 01/01/2022]

[S 796/2022 wef 10/10/2022]

General definitions

2.—(1) In these Regulations, unless the context otherwise requires —

“approved test” means any of the following tests carried out in Singapore in relation to an individual, the purpose of which is to test for the presence of SARS-CoV-2 in that individual:

- (a) a polymerase chain reaction test;
- (b) an antigen rapid test;

“approved test provider” means a person —

- (a) who has an approval under the Infectious Diseases (Antigen Rapid Test Providers) Regulations 2021 (G.N. No. S 267/2021) to provide, in the course of business at any premises in Singapore, a service involving the carrying on of any approved test for hire or reward; or
- (b) to whom a licence is issued under the Private Hospitals and Medical Clinics Act (Cap. 248) to carry on any approved test for hire or reward at any premises in Singapore;

“approved vaccine” means a vaccine described in the First Schedule;

“atypical finding for SARS-CoV-2”, for an individual who undergoes an approved test or tests, means a determination by or under the authority of the Director, or by a legally

qualified medical practitioner in Singapore, that the individual is neither —

- (a) actively infected with a COVID-19 infection; nor
- (b) a carrier of COVID-19,

despite a report by the approved test provider carrying out the approved test or tests that the individual tests positive for SARS-CoV-2;

[S 590/2021 wef 10/08/2021]

[Deleted by S 796/2022 wef 10/10/2022]

[Deleted by S 796/2022 wef 10/10/2022]

[Deleted by S 796/2022 wef 10/10/2022]

“cleared status” means —

- (a) a cleared status (general) that is current; or

[S 908/2021 wef 01/12/2021]

[S 796/2022 wef 10/10/2022]

- (b) a cleared status (special) that is current;

[S 991/2021 wef 01/01/2022]

[S 796/2022 wef 10/10/2022]

- (c) *[Deleted by S 796/2022 wef 10/10/2022]*

[S 590/2021 wef 10/08/2021]

“cleared status certificate” means a certificate granted by the Director under regulation 6(2), (3), (4), (5) or (5A) or 7A(2), (3) or (4) certifying that the individual specified in the certificate has a cleared status according to that regulation;

[S 590/2021 wef 10/08/2021]

[S 908/2021 wef 01/12/2021]

[S 991/2021 wef 01/01/2022]

[S 91/2022 wef 14/02/2022]

[S 445/2022 wef 01/06/2022]

[S 796/2022 wef 10/10/2022]

“cleared status (general)” has the meaning given by regulation 6;

[S 991/2021 wef 01/01/2022]

[Deleted by S 796/2022 wef 10/10/2022]

“cleared status (special)” has the meaning given by regulation 7A;

[S 908/2021 wef 01/12/2021]

“Control Order” means any of the following:

(a) the COVID-19 (Temporary Measures) (Control Order) Regulations 2020 (G.N. No. S 254/2020);

(b) the COVID-19 (Temporary Measures) (Reopening — Control Order) Regulations 2022 (G.N. No. S 179/2022);

[S 180/2022 wef 15/03/2022]

(c) *[Deleted by S 180/2022 wef 15/03/2022]*

(d) *[Deleted by S 180/2022 wef 15/03/2022]*

(e) *[Deleted by S 180/2022 wef 15/03/2022]*

“corresponding foreign authority” means the government or an appropriate authority of a foreign country that has the functions corresponding to the functions of —

(a) the Director —

(i) under these Regulations of certifying that an individual has recovered from a COVID-19 infection in that foreign country;

(ii) under the Infectious Diseases (Antigen Rapid Test Providers) Regulations 2021 of authorising a person to provide in that foreign country the services of an approved test provider; or

(iii) under the Private Hospitals and Medical Clinics Act 1980 of authorising any premises or conveyance in that foreign country to be used as a private hospital, medical clinic, clinical laboratory or healthcare establishment; or

(b) the Singapore Medical Council under the Medical Registration Act 1997 of authorising an individual to practise medicine in that foreign country;

[S 634/2022 wef 29/07/2022]

“COVID-19 naïve individual” means an individual who is not a recovered individual;

[S 91/2022 wef 14/02/2022]

“current”, for any cleared status, has the meaning given by regulation 8A;

[S 590/2021 wef 10/08/2021]

“defined approved vaccine” means —

(a) Sinopharm COVID-19 vaccine; or

(b) Sinovac-Coronavac COVID-19 vaccine;

[S 991/2021 wef 01/01/2022]

“digital cleared status certificate” means a cleared status certificate granted in a digital form described in regulation 4(1);

[Deleted by S 796/2022 wef 10/10/2022]

[Deleted by S 796/2022 wef 10/10/2022]

[Deleted by S 796/2022 wef 10/10/2022]

“foreign ART provider” means a person who is duly authorised by a corresponding foreign authority of a foreign country to provide in the foreign country the services of an approved test provider;

[S 634/2022 wef 29/07/2022]

“foreign country” means any country or territory outside Singapore;

[S 634/2022 wef 29/07/2022]

“foreign healthcare institution” means any premises or conveyance that is duly authorised by a corresponding foreign authority of a foreign country to be used as a

private hospital, medical clinic, clinic laboratory or healthcare establishment in the foreign country;

[S 634/2022 wef 29/07/2022]

“foreign medical practitioner” means an individual who is duly authorised by a corresponding foreign authority of a foreign country to practise medicine in that foreign country;

[S 634/2022 wef 29/07/2022]

[Deleted by S 226/2022 wef 29/03/2022]

“medical treatment” includes a medical consultation, and a diagnostic procedure connected with any medical treatment;

[S 9/2022 wef 06/01/2022]

[Deleted by S 796/2022 wef 10/10/2022]

“nationwide approved vaccine” means any of the following approved vaccines:

(a) Tozinameran (Pfizer-BioNTech COVID-19 vaccine or Comirnaty COVID-19 vaccine);

(b) Spikevax (Moderna COVID-19 vaccine);

[S 69/2022 wef 01/02/2022]

(c) Sinovac-Coronavac COVID-19 vaccine;

(d) COVOVAX COVID-19 vaccine or Nuvaxovid (Novavax COVID-19 vaccine);

[S 445/2022 wef 01/06/2022]

[S 908/2021 wef 01/12/2021]

[Deleted by S 796/2022 wef 10/10/2022]

[Deleted by S 324/2021 wef 16/05/2021]

[Deleted by S 796/2022 wef 10/10/2022]

[Deleted by S 796/2022 wef 10/10/2022]

“primary vaccination” means undergoing a vaccination after which the individual vaccinated is eligible to be granted under regulation 6(4) a certificate stating that he or she has a

cleared status (general) for a definite period of at least 270 days;

[S 91/2022 wef 14/02/2022]

[S 445/2022 wef 01/06/2022]

[Deleted by S 796/2022 wef 10/10/2022]

[Deleted by S 796/2022 wef 10/10/2022]

“recognised medical practitioner”, for any provision of these Regulations, means a legally qualified medical practitioner in Singapore approved by the Director for the purposes of that provision in these Regulations;

“recognised vaccination provider”, in relation to an approved vaccine, means an individual or a body approved by or accredited with the Government, in relation to the approved vaccine, to administer it for the purposes of these Regulations;

[S 590/2021 wef 10/08/2021]

“recovered individual” means an individual who —

- (a) tests positive for SARS-CoV-2 upon undergoing (whether before, on or after 24 April 2021) any of the following:
- (i) a polymerase chain reaction test in or outside Singapore;
 - (ii) an antigen rapid test in Singapore on or after 6 January 2022, and a subsequent serology test in Singapore that is not attributable to the administration of any vaccine against a COVID-19 infection;
 - (iii) an antigen rapid test outside Singapore, where the result is certified by a corresponding foreign authority, foreign medical practitioner, foreign healthcare institution or foreign ART provider;
 - (iv) an antigen rapid test outside Singapore (where the result is not certified in accordance with

sub-paragraph (iii)), and a subsequent serology test in Singapore that is not attributable to the administration of any vaccine against a COVID-19 infection;

- (v) a serology test in or outside Singapore that is not attributable to the administration of any vaccine against a COVID-19 infection, without having tested positive for SARS-CoV-2 upon undergoing a polymerase chain reaction test or an antigen rapid test;
 - (vi) an antigen rapid test in Singapore on or after 6 January 2022 that is performed by or under the direction of the individual's treating doctor in the course of providing medical treatment to the individual because the individual has acute respiratory symptoms;
 - (vii) an antigen rapid test in Singapore (whether before, on or after 23 February 2022) that is performed by or under the direction of an approved test provider or is self-administered by the individual under the supervision of an approved test provider;
- (b) is assessed (whether before, on or after 24 April 2021) as having had a COVID-19 infection; and
- (c) is not actively infected with a COVID-19 infection;

[S 634/2022 wef 29/07/2022]

“relevant assessment activity” means ascertaining the results of an approved test on a respiratory specimen from an individual and recording the results, even if uncertain or invalid;

[S 768/2021 wef 11/10/2021]

[Deleted by S 326/2022 wef 26/04/2022]

“relevant sampling activity” means removing a respiratory specimen from the lining of the oral or nasal passages of an

individual where that is being done for the purpose of a relevant testing activity;

[S 768/2021 wef 11/10/2021]

“relevant start date”, in relation to any COVID-19 infection of a recovered individual, means —

(a) in a case falling within paragraph (a)(v) of the definition of “recovered individual” read with paragraphs (b) and (c) of that definition —

(i) the date that the individual first tested positive for SARS-CoV-2 upon undergoing the serology test in or outside Singapore that led to the assessment of the individual having the COVID-19 infection; or

(ii) such earlier date (if any) that is certified by a registered medical practitioner in Singapore as the date that the individual is first assessed as having had the COVID-19 infection; or

(b) in any other case — the date that the individual first tested positive for SARS-CoV-2 upon undergoing the test or series of tests under paragraph (a)(i), (ii), (iii), (iv), (vi), or (vii) of the definition of “recovered individual”, which led to the assessment of the individual having the COVID-19 infection;

[S 634/2022 wef 29/07/2022]

“relevant testing activity” means subjecting the respiratory specimen from an individual to an approved test for the purpose of testing the presence of SARS-CoV-2 in that individual;

[S 768/2021 wef 11/10/2021]

“respiratory specimen” includes human biological tissue, saliva or mucus;

[Deleted by S 796/2022 wef 10/10/2022]

[Deleted by S 796/2022 wef 10/10/2022]

[Deleted by S 326/2022 wef 26/04/2022]

[Deleted by S 796/2022 wef 10/10/2022]

[Deleted by S 796/2022 wef 10/10/2022]

[Deleted by S 796/2022 wef 10/10/2022]

[Deleted by S 326/2022 wef 26/04/2022]

[Deleted by S 796/2022 wef 10/10/2022]

[Deleted by S 796/2022 wef 10/10/2022]

[Deleted by S 796/2022 wef 10/10/2022]

[Deleted by S 69/2022 wef 01/02/2022]

“treating doctor”, for an individual, means a legally qualified medical practitioner who, in the course of providing medical treatment of the individual as a patient thereof, assesses the individual’s condition, whether remotely or in person;

[S 9/2022 wef 06/01/2022]

“Type S recovered individual” means a recovered individual because he or she tested positive for SARS-CoV-2 upon undergoing a test mentioned in paragraph (a)(v) of the definition of “recovered individual”;

[S 91/2022 wef 14/02/2022]

[S 634/2022 wef 29/07/2022]

“Type T recovered individual” means a recovered individual because he or she tested positive for SARS-CoV-2 upon undergoing a test mentioned in paragraph (a)(i), (ii), (iii), (iv), (vi) or (vii) of the definition of “recovered individual”;

[S 91/2022 wef 14/02/2022]

[S 102/2022 wef 24/02/2022]

[S 634/2022 wef 29/07/2022]

[Deleted by S 796/2022 wef 10/10/2022]

“vaccinated” means vaccinated against a COVID-19 infection by a recognised vaccination provider using (whether before, on or after 10 August 2021) an approved vaccine or a

combination of approved vaccines in the way described in the First Schedule.

[S 324/2021 wef 16/05/2021]

[S 513/2021 wef 12/07/2021]

[S 590/2021 wef 10/08/2021]

[S 908/2021 wef 01/12/2021]

[S 796/2022 wef 10/10/2022]

[Deleted by S 796/2022 wef 10/10/2022]

[Deleted by S 324/2021 wef 16/05/2021]

(2) For the purposes of these Regulations, an individual is treated as undergoing or having undergone an approved test where an approved test is applied to any respiratory specimen taken from the individual in the course of a relevant sampling activity.

(3) In reckoning a period for the purposes of these Regulations, days must be counted consecutively, whether or not a public holiday.

(4) To avoid doubt, for the purpose of determining whether an individual is vaccinated, any amendment to the First Schedule which inserts, or deletes and substitutes, any vaccine in the First Schedule applies in relation to any individual who is administered that vaccine even before the date the amendment to that Schedule comes into operation.

[S 908/2021 wef 01/12/2021]

(5) *[Deleted by S 474/2022 wef 14/06/2022]*

(6) *[Deleted by S 796/2022 wef 10/10/2022]*

3. *[Deleted by S 796/2022 wef 10/10/2022]*

Digital certificates and automated decision making, etc.

4.—(1) To avoid doubt, a cleared status certificate may be granted under these Regulations in a digital form, consisting of evidence of the grant of the certificate (using information about the individual to whom the certificate relates) that is displayed on a mobile communication device or other electronic device.

[S 317/2022 wef 19/04/2022]

[S 474/2022 wef 14/06/2022]

(2) For the purposes of these Regulations, any decision, assessment or certification which may be made or granted by the Director under any provision in these Regulations may also be made or granted —

- (a) by a public officer or other individual acting under the authority of the Director; or
- (b) by a computer for whose operation the Director or a public officer mentioned in sub-paragraph (a) is responsible.

5. [*Deleted by S 796/2022 wef 10/10/2022*]

PART 2

CLEARED STATUS AND NEGATIVE RESULTS

Meaning of “cleared status (general)”

6.—(1) For the purposes of these Regulations, an individual is treated as having a cleared status (general) only if he or she is and to the extent certified under this regulation as having a cleared status (general).

[S 590/2021 wef 10/08/2021]

[S 908/2021 wef 01/12/2021]

(2) Where the Director or a recognised medical practitioner is satisfied that an individual is a recovered individual, the Director or recognised medical practitioner (as the case may be) may grant a certificate stating that the individual has a cleared status (general) for a period —

- (a) for a recovered individual who was never vaccinated against a COVID-19 infection before he or she was assessed as having the COVID-19 infection —

- (i) starting on the relevant start date for the COVID-19 infection; and

[S 634/2022 wef 29/07/2022]

- (ii) ending on (and including) as follows:

- (A) the 180th day after the date in sub-paragraph (i), unless sub-paragraph (B) applies;

(B) 31 January 2022, where the individual is a transitional case; or

[S 991/2021 wef 01/01/2022]

[S 590/2021 wef 10/08/2021]

[S 102/2022 wef 24/02/2022]

(b) for a recovered individual who is assessed as having a COVID-19 infection upon undergoing the test or series of tests under paragraph (a)(i), (ii), (iii), (iv), (vi) or (vii) of the definition of “recovered individual”, after a certificate under this paragraph had been granted in respect of the individual, and who was never vaccinated against a COVID-19 infection, the period falling after the grant of the certificate —

(i) starting on the relevant start date for that COVID-19 infection; and

[S 634/2022 wef 29/07/2022]

(ii) ending on (and including) as follows:

(A) the 180th day after the date in sub-paragraph (i), unless sub-paragraph (B) applies;

(B) 31 January 2022, where the individual is a transitional case.

[S 991/2021 wef 01/01/2022]

[S 590/2021 wef 10/08/2021]

[S 102/2022 wef 24/02/2022]

[S 634/2022 wef 29/07/2022]

(3) Where the Director is satisfied that —

(a) an individual is a recovered individual; and

(b) the individual is vaccinated against a COVID-19 infection by the administration of any approved vaccine by a recognised vaccination provider,

the Director may grant a certificate stating that the recovered individual has a cleared status (general) for a period as follows, whichever is applicable:

- (c) for an indefinite period starting the day stated in the First Schedule corresponding to the approved vaccine used in the vaccination and the nature of the individual's vaccination;
- (d) for a period that starts and ends as stated in the First Schedule corresponding to the approved vaccine used in the vaccination and the nature of the individual's vaccination.

[S 91/2022 wef 14/02/2022]

(4) In addition, where the Director is satisfied that an individual who is a COVID-19 naïve individual is vaccinated against a COVID-19 infection by the administration of any approved vaccine by a recognised vaccination provider, the Director may grant a certificate stating that the individual has a cleared status (general) for a period as follows, whichever is applicable:

- (a) unless sub-paragraph (b) applies —
 - (i) for an indefinite period starting the day stated in the First Schedule corresponding to the approved vaccine used in the vaccination and the nature of the individual's vaccination; or
 - (ii) for a period that starts and ends as stated in the First Schedule corresponding to the approved vaccine used in the vaccination and the nature of the individual's vaccination;
- (b) if the COVID-19 naïve individual undergoes a primary vaccination before attaining 12 years of age, for a period that —
 - (i) starts as stated in the First Schedule corresponding to the approved vaccine used in the vaccination and the nature of the individual's vaccination; and
 - (ii) ends at the expiry of 2 months after the individual attains 12 years of age or the end date stated in the First Schedule corresponding to the approved

vaccine used in the individual's primary vaccination, whichever date is later.

[S 180/2022 wef 14/03/2022]

[S 91/2022 wef 14/02/2022]

(5) Despite paragraph (2), (3) or (4), where an individual is assessed as having a COVID-19 infection, after he or she underwent vaccination and is granted a certificate under paragraph (3) or (4), the Director or a recognised medical practitioner may, where satisfied that the individual is a recovered individual after that infection or any later infection, grant a certificate stating that the individual has a cleared status (general) for a period as follows, whichever is applicable:

(a) if the recovered individual underwent only a primary vaccination — for the period specified in sub-paragraph (i) or (ii), whichever ends later:

(i) 270 days, starting the date the last dose of the primary vaccination was administered on the recovered individual;

(ii) 180 days, starting on the relevant start date for the last infection;

[S 634/2022 wef 29/07/2022]

[S 445/2022 wef 01/06/2022]

(b) if the recovered individual was granted a certificate under paragraph (4) stating that the individual has a cleared status (general) for a period of 120 days — for a period of 270 days starting on the relevant start date for that infection;

[S 634/2022 wef 29/07/2022]

(c) if the recovered individual was granted a certificate under paragraph (3)(d) — for a period starting on the relevant start date for the last infection and ending on the later of the following:

(i) the last day of the period mentioned in paragraph (3)(d);

(ii) the 180th day.

[S 634/2022 wef 29/07/2022]

[S 91/2022 wef 14/02/2022]

[S 102/2022 wef 24/02/2022]

(5A) Where paragraph (5)(a) or (b) applies, the Director or a recognised medical practitioner may, where satisfied that the recovered individual has been administered another dose of any approved vaccine (whether before, on or after 1 June 2022), grant a certificate stating the individual has a cleared status (general) for an indefinite period starting the date that other dose is administered if —

- (a) in the case of paragraph (5)(a) — the other dose is administered at least 86 days after the date the last dose of the primary vaccination was administered on the recovered individual;
- (b) in the case of paragraph (5)(b) — the other dose is administered at least 86 days after the relevant start date for that infection.

[S 634/2022 wef 29/07/2022]

[S 445/2022 wef 01/06/2022]

(6) The Director may cancel any certificate granted under this regulation stating that an individual has a cleared status (general) if —

- (a) *[Deleted by S 9/2022 wef 06/01/2022]*
- (b) the Director is satisfied that it is the interest of the health and safety of the individual to do so.

[S 590/2021 wef 10/08/2021]

(7) To avoid doubt, the period in paragraph (3), (4) or (5) may be a period before 24 April 2021.

[S 590/2021 wef 10/08/2021]

(8) An individual is a transitional case for the purposes of paragraph (2) —

- (a) if he or she had acquired, before 1 January 2022, a cleared status (general) under paragraph (2), and would have continued on or after that date to have a cleared status (general) if not for the making of the Infectious Diseases

(Mass Gathering Testing for Coronavirus Disease 2019) (Amendment No. 14) Regulations 2021; but

- (b) not if he or she had acquired, before 1 January 2022, a cleared status (general) under paragraph (2) and ceased to have a cleared status (general) that is current before that date because of regulation 8A(1)(a) or (c).

[S 991/2021 wef 01/01/2022]

7. *[Deleted by S 474/2022 wef 14/06/2022]*

Meaning of “cleared status (special)”

7A.—(1) For the purposes of these Regulations, an individual is treated as having a cleared status (special) only if he or she is and to the extent certified under this regulation as having a cleared status (special).

(2) Where the Director or a legally qualified medical practitioner diagnoses that an individual (of any age) without a cleared status (general) that is current, has a severe immunocompromising condition, or is undergoing or about to undergo an immunosuppressive therapy, anticipated to affect the suitability of the individual to be vaccinated against a COVID-19 infection using the nationwide approved vaccines, because the individual —

- (a) has undergone an organ transplant and is or was a recipient of an organ of a human body;
- (b) is undergoing aggressive immunotherapy;
- (c) is undergoing or is about to undergo active cancer treatment; or
- (d) has undergone active cancer treatment,

the Director or legally qualified medical practitioner (as the case may be) may grant a certificate stating that the individual has a cleared status (special) for a period corresponding to the period of unsuitability to be so vaccinated —

- (e) starting the date the individual is so diagnosed; and
- (f) ending when the period specified in the certificate expires, being no longer than the applicable period as follows:

- (i) for an individual mentioned in sub-paragraph (a) — 6 months after the date of the individual's organ transplant operation;

[S 445/2022 wef 01/06/2022]

- (ii) for an individual mentioned in sub-paragraph (b) or (c) — 6 months after the individual is diagnosed as having a severe immunocompromising condition, or undergoing or about to undergo an immunosuppressive therapy, anticipated to affect the suitability of the individual to be vaccinated against a COVID-19 infection using the nationwide approved vaccines;

[S 445/2022 wef 01/06/2022]

- (iii) for an individual mentioned in sub-paragraph (d) — 3 months after the date of the last occasion when the individual underwent that active cancer treatment.

(3) Where the Director or a legally qualified medical practitioner diagnoses that an individual who is at least 18 years of age has a medical contraindication to vaccination using every nationwide approved vaccine because the individual has or is assessed to be at greater risk of developing —

(a) an allergic reaction; or

(b) a severe adverse reaction that is not an allergic reaction,

if administered with a dose of any of the nationwide approved vaccines, the Director or legally qualified medical practitioner (as the case may be) may grant a certificate stating that the individual has a cleared status (special) for a period —

(c) starting the date the individual is so diagnosed; and

(d) ending when the period specified in the certificate expires, being no longer than 365 days after that diagnosis.

(3A) Despite paragraph (2) or (3), if a certificate is granted under that paragraph in respect of an individual on or before 31 May 2022, the certificate expires on —

(a) the date that the period specified in the certificate expires;
or

(b) 1 August 2022,
whichever is earlier.

[S 445/2022 wef 01/06/2022]

(4) Where the Director or a legally qualified medical practitioner diagnoses that an individual who is at least 12 years of age but below 18 years of age has a medical contraindication to vaccination using Tozinameran (Pfizer-BioNTech COVID-19 vaccine or Comirnaty COVID-19 vaccine) because the individual has or is assessed to be at greater risk of developing —

(a) an allergic reaction; or

(b) a severe adverse reaction that is not an allergic reaction, if administered with a dose of Tozinameran (Pfizer-BioNTech COVID-19 vaccine or Comirnaty COVID-19 vaccine), the Director or legally qualified medical practitioner (as the case may be) may grant a certificate stating that the individual has a cleared status (special) for a period —

(c) starting the date the individual is so diagnosed; and

(d) ending on whichever of the following first occurs:

(i) when the period specified in the certificate expires, being no longer than 365 days after that diagnosis; or

(ii) the individual attains 18 years of age.

(5) To avoid doubt —

(a) the period in paragraph (2), (3) or (4) may consist of a period before 1 December 2021; and

(b) the Director or a legally qualified medical practitioner may grant more than one certificate under paragraph (2), (3) or (4) in respect of the same individual upon the expiry of an earlier certificate granted to that individual.

(6) The Director may cancel any certificate granted under this regulation stating that an individual has a cleared status (special) if —

(a) *[Deleted by S 9/2022 wef 06/01/2022]*

- (b) the Director is satisfied that it is the interest of the health and safety of the individual to do so.

[S 908/2021 wef 01/12/2021]

7B. *[Deleted by S 796/2022 wef 10/10/2022]*

What is negative test result

8.—(1) For the purposes of these Regulations, where an individual undergoes an approved test or tests consisting only of a polymerase chain reaction test or tests, the individual's test result is treated as negative for SARS-CoV-2 only if —

- (a) the test result from the sole polymerase chain reaction test the individual undergoes shows no presence of SARS-CoV-2 in that individual or the individual's test result shows the presence of SARS-CoV-2 in that individual but it is an atypical finding for SARS-CoV-2; or

[S 590/2021 wef 10/08/2021]

- (b) the test result from the last polymerase chain reaction test the individual undergoes shows no presence of SARS-CoV-2 in that individual, after the individual undergoes further polymerase chain reaction tests and the test results of those tests are uncertain or invalid except the last, or the individual's last test result shows the presence of SARS-CoV-2 in that individual but it is an atypical finding for SARS-CoV-2.

[S 590/2021 wef 10/08/2021]

(2) For the purposes of these Regulations, where an individual undergoes an approved test or tests consisting only of an antigen rapid test or tests, the individual's test result is treated as negative for SARS-CoV-2 only if —

- (a) the antigen rapid test result from the sole antigen rapid test the individual undergoes shows no presence of SARS-CoV-2 in that individual; or

- (b) the test result from the last antigen rapid test the individual undergoes shows no presence of SARS-CoV-2 in that individual, after the individual undergoes further antigen

rapid tests and the test results of those tests are uncertain or invalid except the last.

[S 768/2021 wef 11/10/2021]

(3) For the purposes of these Regulations, where an individual undergoes a series of approved tests consisting of polymerase chain reaction tests and antigen rapid tests, the individual's test result is treated as negative for SARS-CoV-2 only if —

(a) the test results of the antigen rapid tests are uncertain or invalid, another respiratory specimen from the individual is then subjected to a polymerase chain reaction test, and —

(i) the test result from that polymerase chain reaction test the individual undergoes shows no presence of SARS-CoV-2 in that individual or the individual's test result shows the presence of SARS-CoV-2 in that individual but it is an atypical finding for SARS-CoV-2; or

[S 590/2021 wef 10/08/2021]

(ii) the test result from the last polymerase chain reaction test the individual undergoes shows no presence of SARS-CoV-2 in that individual, after the individual undergoes further polymerase chain reaction tests and the test results of those tests are uncertain or invalid except the last, or the individual's last test result shows the presence of SARS-CoV-2 in that individual but it is an atypical finding for SARS-CoV-2; or

[S 590/2021 wef 10/08/2021]

[S 768/2021 wef 11/10/2021]

(b) the test result of an antigen rapid test shows the presence of SARS-CoV-2 in that individual, another respiratory specimen from the individual is then subjected to a polymerase chain reaction test, and —

(i) the test result from that polymerase chain reaction test the individual undergoes shows no presence of SARS-CoV-2 in that individual or the individual's test result shows the presence of SARS-CoV-2 in that

individual but it is an atypical finding for SARS-CoV-2; or

[S 590/2021 wef 10/08/2021]

- (ii) the test result from the last polymerase chain reaction test the individual undergoes shows no presence of SARS-CoV-2 in that individual, after the individual undergoes further polymerase chain reaction tests and the test results of those tests are uncertain or invalid except the last, or the individual's last test result shows the presence of SARS-CoV-2 in that individual but it is an atypical finding for SARS-CoV-2.

[S 590/2021 wef 10/08/2021]

(4) Despite paragraphs (1), (2) and (3), a result of an antigen rapid test for the presence of SARS-CoV-2 applied to an individual's respiratory specimen must be disregarded for the purposes of these Regulations if —

- (a) the relevant sampling activity taking the respiratory specimen from the individual was —

- (i) not performed in Singapore, or not performed by or under the direction of an approved test provider where the relevant sampling activity is not self-administered; or
- (ii) in the case of a self-administered relevant sampling activity performed by the individual on himself or herself, not supervised by an approved test provider; or

[S 768/2021 wef 11/10/2021]

- (b) the relevant testing activity or the relevant assessment activity involving the respiratory specimen from the individual was —

- (i) not performed in Singapore, or not performed by or under the direction of an approved test provider where the relevant testing activity or the relevant assessment activity is not self-administered; or

- (ii) in the case of a self-administered relevant testing activity or a self-administered relevant assessment activity performed by the individual involving the respiratory specimen removed from himself or herself, not supervised by an approved test provider.

[S 768/2021 wef 11/10/2021]

When is cleared status current

8A.—(1) For the purposes of these Regulations, an individual who has a cleared status (general) because he or she is granted a certificate under regulation 6(2) does not have a cleared status (general) that is current —

- (a) after the end of the period specified in and applicable to the individual under regulation 6(2); or

[S 69/2022 wef 01/02/2022]

- (b) *[Deleted by S 69/2022 wef 01/02/2022]*

- (c) after the certificate under regulation 6(2) is cancelled.

(2) For the purposes of these Regulations, an individual who has a cleared status (general) other than for an indefinite period because he or she is granted a certificate under regulation 6(3), (4) or (5) does not have a cleared status (general) that is current —

- (a) after the end of the period referred to in and applicable to the individual under regulation 6(3), (4) or (5), as the case may be; or

[S 69/2022 wef 01/02/2022]

- (b) *[Deleted by S 69/2022 wef 01/02/2022]*

- (c) after the cancellation of the certificate under regulation 6(3), (4) or (5), as the case may be.

[S 991/2021 wef 01/01/2022]

[S 91/2022 wef 14/02/2022]

(3) For the purposes of these Regulations, an individual who has a cleared status (general) for an indefinite period because he or she is granted a certificate under regulation 6(3), (4) or (5) does not have a

cleared status (general) that is current after the cancellation of the certificate under regulation 6(6).

[S 91/2022 wef 14/02/2022]

(3A) For the purposes of these Regulations, an individual who has a cleared status (special) because he or she is granted a certificate under regulation 7A(2), (3) or (4) does not have a cleared status (special) that is current —

- (a) after the end of the period referred to in and applicable to the individual under regulation 7A(2), (3) or (4), as the case may be; or

[S 69/2022 wef 01/02/2022]

- (b) [Deleted by S 69/2022 wef 01/02/2022]

- (c) after the cancellation under regulation 7A(6) of the certificate.

[S 908/2021 wef 01/12/2021]

- (3B) [Deleted by S 796/2022 wef 10/10/2022]

- (4) [Deleted by S 69/2022 wef 01/02/2022]

- (5) [Deleted by S 69/2022 wef 01/02/2022]

[S 590/2021 wef 10/08/2021]

PART 3

[Deleted by S 796/2022 wef 10/10/2022]

FIRST SCHEDULE

Regulations 2(1) and (4) and 6(3)
and (4)

VACCINATION AND APPROVED VACCINES

| <i>First column</i> | <i>Second column</i> | <i>Third column</i> | <i>Fourth column</i> |
|---------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|---------------------------------------------------------------|
| <i>Approved vaccine</i> | <i>Vaccination</i> | <i>Start</i> | <i>End</i> |
| 1. Tozinameran (Pfizer-BioNTech COVID-19 vaccine or Comirnaty COVID-19 vaccine) | (1) One dose of the approved vaccine opposite, administered to a Type T recovered individual at least | 14th day after the dose is administered in accordance with the second column. | 270th day (including that day) after the dose is administered |

FIRST SCHEDULE — *continued*

| | | | |
|--|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| | 28 days after the relevant start date for the COVID-19 infection concerned. | | |
| | (2) One dose of the approved vaccine opposite, administered to a Type S recovered individual after his or her recovery from the COVID-19 infection. | 14th day after the dose is administered in accordance with the second column. | 270th day (including that day) after the day the dose is administered. |
| | (2A) Vaccination in accordance with paragraph (1) or (2), followed by another dose of any approved vaccine, administered at least 86 days after the day the first dose is administered. | The day the second dose is administered in accordance with the second column. | Indefinite after the start of the period. |
| | (3) Two doses of the approved vaccine opposite, administered at least 17 days apart. | 14th day after the second dose is administered in accordance with the second column. | 270th day (including that day) after the day the second dose is administered. |
| | (4) One dose of the approved vaccine opposite, followed by a dose of another approved vaccine that is not a defined approved vaccine, administered at least 17 days after the firstmentioned dose is administered. | 14th day after the second dose is administered in accordance with the second column. | 270th day (including that day) after the second dose is administered. |

FIRST SCHEDULE — *continued*

| | | | |
|--|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | (5) One dose of the approved vaccine opposite, followed by a dose of a defined approved vaccine, administered at least 17 days after the firstmentioned dose is administered. | 14th day after the second dose is administered in accordance with the second column. | 120th day (including that day) after the day the second dose is administered. |
| | (6) Two doses of the approved vaccine opposite or one dose thereof in combination with a dose of another approved vaccine where the doses are administered at such other intervals as may be allowed by the Director. | 14th day after the second dose is administered in accordance with the second column. | The following day (including that day) after the day the second dose is administered: (a) 120th day where the second dose is a defined approved vaccine; (b) 270th day for any other approved vaccine. |
| | (7) Three doses of the approved vaccine opposite, where the first 2 doses are administered at least 17 days apart, and where the second and third doses are administered at least 86 days apart. | The day the third dose is administered in accordance with the second column. | Indefinite after the start of the period. |
| | (8) Two doses of the approved vaccine opposite, followed by one | The day the third dose is administered in | Indefinite after the start of the period. |

FIRST SCHEDULE — *continued*

| | | | |
|--|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| | dose of another approved vaccine, where the first 2 doses are administered at least 17 days apart, and where the second and third doses are administered at least 86 days apart. | accordance with the second column. | |
| | (9) One dose of the approved vaccine opposite, followed by 2 doses of another approved vaccine that is not a defined approved vaccine or a combination of approved vaccines none of which is a defined approved vaccine, where the first 2 doses are administered at least 17 days apart, and where the second and third doses are administered at least 86 days apart. | The day the third dose is administered in accordance with the second column. | Indefinite after the start of the period. |
| | (10) One dose of the approved vaccine opposite, followed by 2 doses of any defined approved vaccine or combination of defined approved vaccines, where the respective doses are each administered at | The day the third dose is administered in accordance with the second column. | 270th day (including that day) after the day the third dose is administered. |

FIRST SCHEDULE — *continued*

| | | | |
|--|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | least 17 days apart. | | |
| | (11) Vaccination in accordance with paragraph (6) where the second dose is a defined approved vaccine, followed by another dose of any defined approved vaccine, where the second and third doses are administered at least 17 days apart. | The day the third dose is administered in accordance with the second column. | 270th day (including that day) after the day the third dose is administered. |
| | (12) Vaccination in accordance with paragraph (6) where the second dose is an approved vaccine that is not a defined approved vaccine, followed by a third dose of any approved vaccine that is not a defined approved vaccine, where the second and third doses are administered at least 86 days apart. | The day the third dose is administered in accordance with the second column. | Indefinite after the start of the period. |
| | (13) At least 3 doses one of which is the approved vaccine opposite, and where the second and third doses are administered at a shorter interval than as specified | The day the third dose is administered in accordance with the second column. | 270th day (including that day) after the day the second dose is administered plus a period fixed by the Director, being not more than 85 days and corresponding to |

FIRST SCHEDULE — *continued*

| | | | |
|----------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | in paragraph (7), (8), (9) or (12) and allowed by the Director. | | the actual interval between the second and third doses. |
| | (14) Vaccination in accordance with paragraph (10) followed by a fourth dose of any approved vaccine administered at least 86 days after the third dose is administered. | The day the fourth dose is administered in accordance with the second column. | Indefinite after the start of the period. |
| | (15) At least 4 doses where vaccination is in accordance with paragraph (10) for the first 3 doses and the fourth dose is any approved vaccine, and where the third and fourth doses are administered at a shorter interval than as specified in paragraph (14) and allowed by the Director. | The day the fourth dose is administered in accordance with the second column. | 270th day (including that day) after the day the third dose is administered plus a period fixed by the Director, being not more than 85 days and corresponding to the actual interval between the third and fourth doses. |
| 2. Spikevax (Moderna COVID-19 vaccine) | (1) One dose of the approved vaccine opposite, administered to a Type T recovered individual at least 28 days after the relevant start date for the COVID-19 infection concerned. | 14th day after the dose is administered in accordance with the second column. | 270th day (including that day) after the day the dose is administered. |
| | (2) One dose of the approved vaccine | 14th day after the dose is | 270th day (including that |

FIRST SCHEDULE — *continued*

| | | | |
|--|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| | opposite, administered to a Type S recovered individual after his or her recovery from the COVID-19 infection. | administered in accordance with the second column. | day) after the day the dose is administered. |
| | (2A) Vaccination in accordance with paragraph (1) or (2), followed by another dose of any approved vaccine, administered at least 86 days after the day the first dose is administered. | The day the second dose is administered in accordance with the second column. | Indefinite after the start of the period. |
| | (3) Two doses of the approved vaccine opposite, administered at least 24 days apart. | 14th day after the second dose is administered in accordance with the second column. | 270th day (including that day) after the day the second dose is administered. |
| | (4) One dose of the approved vaccine opposite, followed by a dose of another approved vaccine that is not a defined approved vaccine, administered at least 17 days after the firstmentioned dose is administered. | 14th day after the second dose is administered in accordance with the second column. | 270th day (including that day) after the day the second dose is administered. |
| | (5) One dose of the approved vaccine opposite, followed by a dose of a defined approved vaccine, | 14th day after the second dose is administered in accordance with the second column. | 120th day (including that day) after the day the second dose is administered. |

FIRST SCHEDULE — *continued*

| | | | |
|--|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | administered at least 17 days after the firstmentioned dose is administered. | | |
| | (6) Two doses of the approved vaccine opposite or one dose thereof in combination with a dose of another approved vaccine, where the doses are administered at such other intervals as may be allowed by the Director. | 14th day after the second dose is administered in accordance with the second column. | The following day (including that day) after the day the second dose is administered: (a) 120th day where the second dose is a defined approved vaccine; (b) 270th day for any other approved vaccine. |
| | (7) Three doses of the approved vaccine opposite, where the first 2 doses are administered at least 24 days apart, and where the second and third doses are administered at least 86 days apart. | The day the third dose is administered in accordance with the second column. | Indefinite after the start of the period. |
| | (8) Two doses of the approved vaccine opposite followed by one dose of any other approved vaccine, where the first 2 doses are administered at least 24 days apart, and where | The day the third dose is administered in accordance with the second column. | Indefinite after the start of the period. |

FIRST SCHEDULE — *continued*

| | | | |
|--|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| | the second and third doses are administered at least 86 days apart. | | |
| | (9) One dose of the approved vaccine opposite, followed by 2 doses of another approved vaccine that is not a defined approved vaccine or a combination of approved vaccines none of which is a defined approved vaccine, where the first 2 doses are administered at least 17 days apart, and where the second and third doses are administered at least 86 days apart. | The day the third dose is administered in accordance with the second column. | Indefinite after the start of the period. |
| | (10) One dose of the approved vaccine opposite, followed by 2 doses of any defined approved vaccine or combination of defined approved vaccines, where the respective doses are each administered at least 17 days apart. | The day the third dose is administered in accordance with the second column. | 270th day (including that day) after the day the third dose is administered. |
| | (11) Vaccination in accordance with paragraph (6) where the second | The day the third dose is administered in | 270th day (including that day) after the day |

FIRST SCHEDULE — *continued*

| | | | |
|--|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | dose is a defined approved vaccine, followed by another dose of any defined approved vaccine, where the second and third doses are administered at least 17 days apart. | accordance with the second column. | the third dose is administered. |
| | (12) Vaccination in accordance with paragraph (6) where the second dose is an approved vaccine that is not a defined approved vaccine, followed by a third dose of any approved vaccine that is not a defined approved vaccine, where the second and third doses are administered at least 86 days apart. | The day the third dose is administered in accordance with the second column. | Indefinite after the start of the period. |
| | (13) At least 3 doses of approved vaccines, one of which is the approved vaccine opposite, and where the second and third doses are administered at a shorter interval than as specified in paragraph (7), (8), (9) or (12) and allowed by the Director. | The day the third dose is administered in accordance with the second column. | 270th day (including that day) after the day the second dose is administered plus a period fixed by the Director, being not more than 85 days and corresponding to the actual interval between the second and third doses. |

FIRST SCHEDULE — *continued*

| | | | |
|----------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | (14) Vaccination in accordance with paragraph (10) followed by a fourth dose of any approved vaccine administered at least 86 days after the third dose is administered. | The day the fourth dose is administered in accordance with the second column. | Indefinite after the start of the period. |
| | (15) At least 4 doses where vaccination is in accordance with paragraph (10) for the first 3 doses and the fourth dose is any approved vaccine, and where the third and fourth doses are administered at a shorter interval than as specified in paragraph (14) and allowed by the Director. | The day the fourth dose is administered in accordance with the second column. | 270th day (including that day) after the day the third dose is administered plus a period fixed by the Director, being not more than 85 days and corresponding to the actual interval between the third and fourth doses. |
| 3. Covishield COVID-19 vaccine or Vaxzevria (AstraZeneca COVID-19 vaccine) | (1) One dose of the approved vaccine opposite, administered to a Type T recovered individual at least 28 days after the relevant start date for the COVID-19 infection concerned. | 14th day after the dose is administered in accordance with the second column. | 270th day (including that day) after the day the dose is administered. |
| | (2) One dose of the approved vaccine opposite, administered to a Type S recovered individual after | 14th day after the dose is administered in accordance with the second column. | 270th day (including that day) after the day the dose is administered. |

FIRST SCHEDULE — *continued*

| | | | |
|--|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| | his or her recovery from the COVID-19 infection. | | |
| | (2A) Vaccination in accordance with paragraph (1) or (2), followed by another dose of any approved vaccine, administered at least 86 days after the day the first dose is administered. | The day the second dose is administered in accordance with the second column. | Indefinite after the start of the period. |
| | (3) Two doses of the approved vaccine opposite, administered at least 24 days apart. | 14th day after the second dose is administered in accordance with the second column. | 270th day (including that day) after the day the second dose is administered. |
| | (4) One dose of the approved vaccine opposite, followed by a dose of another approved vaccine that is not a defined approved vaccine, administered at least 17 days after the firstmentioned dose is administered. | 14th day after the second dose is administered in accordance with the second column. | 270th day (including that day) after the day the second dose is administered. |
| | (5) One dose of the approved vaccine opposite, followed by a dose of a defined approved vaccine, administered at least 17 days after the firstmentioned | 14th day after the second dose is administered in accordance with the second column. | 120th day (including that day) after the day the second dose is administered. |

FIRST SCHEDULE — *continued*

| | dose is administered. | | |
|--|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | (6) Two doses of the approved vaccine opposite or one dose thereof in combination with a dose of another approved vaccine, where the doses are administered at such other intervals as may be allowed by the Director. | 14th day after the second dose is administered in accordance with the second column. | The following day (including that day) after the day the second dose is administered: (a) 120th day where the second dose is a defined approved vaccine; (b) 270th day for any other approved vaccine. |
| | (7) Three doses of the approved vaccine opposite, where the first 2 doses are administered at least 24 days apart, and where the second and third doses are administered at least 86 days apart. | The day the third dose is administered in accordance with the second column. | Indefinite after the start of the period. |
| | (8) Two doses of the approved vaccine opposite administered at least 24 days apart, followed by one dose of another approved vaccine administered at least 86 days after the second dose is administered. | The day the third dose is administered in accordance with the second column. | Indefinite after the start of the period. |

FIRST SCHEDULE — *continued*

| | | | |
|--|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| | (9) One dose of the approved vaccine opposite, followed by 2 doses of another approved vaccine that is not a defined approved vaccine or a combination of approved vaccines none of which is a defined approved vaccine, where the first 2 doses are administered at least 17 days apart, and where the second and third doses are administered at least 86 days apart. | The day the third dose is administered in accordance with the second column. | Indefinite after the start of the period. |
| | (10) One dose of the approved vaccine opposite, followed by 2 doses of any defined approved vaccine or combination of defined approved vaccines, where the respective doses are each administered at least 17 days apart. | The day the third dose is administered in accordance with the second column. | 270th day (including that day) after the day the third dose is administered. |
| | (11) Vaccination in accordance with paragraph (6) where the second dose is a defined approved vaccine, followed by another dose of any defined approved | The day the third dose is administered in accordance with the second column. | 270th day (including that day) after the day the third dose is administered. |

FIRST SCHEDULE — *continued*

| | | | |
|--|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | vaccine, where the second and third doses are administered at least 17 days apart. | | |
| | (12) Vaccination in accordance with paragraph (6) where the second dose is an approved vaccine that is not a defined approved vaccine, followed by a third dose of any approved vaccine that is not a defined approved vaccine, where the second and third doses are administered at least 86 days apart. | The day the third dose is administered in accordance with the second column. | Indefinite after the start of the period. |
| | (13) At least 3 doses of approved vaccines, one of which is the approved vaccine opposite, and where the second and third doses are administered at a shorter interval than as specified in paragraph (7), (8), (9) or (12) and allowed by the Director. | The day the third dose is administered in accordance with the second column. | 270th day (including that day) after the day the second dose is administered plus a period fixed by the Director, being not more than 85 days and corresponding to the actual interval between the second and third doses. |
| | (14) Vaccination in accordance with paragraph (10) followed by a fourth dose of any approved | The day the fourth dose is administered in accordance with the second column. | Indefinite after the start of the period. |

FIRST SCHEDULE — *continued*

| | | | |
|-------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | vaccine administered at least 86 days after the third dose is administered. | | |
| | (15) At least 4 doses where vaccination is in accordance with paragraph (10) for the first 3 doses and the fourth dose is any approved vaccine, and where the third and fourth doses are administered at a shorter interval than as specified in paragraph (14) and allowed by the Director. | The day the fourth dose is administered in accordance with the second column. | 270th day (including that day) after the day the third dose is administered plus a period fixed by the Director, being not more than 85 days and corresponding to the actual interval between the third and fourth doses. |
| 4. Johnson & Johnson's (J&J) Janssen COVID-19 vaccine | (1) One dose of the approved vaccine opposite, administered to a Type T recovered individual at least 28 days after the relevant start date for the COVID-19 infection concerned. | 14th day after the dose is administered in accordance with the second column. | 270th day (including that day) after the day the dose is administered. |
| | (2) One dose of the approved vaccine opposite, administered to a Type S recovered individual after his or her recovery from the COVID-19 infection. | 14th day after the dose is administered in accordance with the second column. | 270th day (including that day) after the day the dose is administered. |

FIRST SCHEDULE — *continued*

| | | | |
|-------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | (2A) Vaccination in accordance with paragraph (1) or (2), followed by another dose of any approved vaccine, administered at least 86 days after the day the first dose is administered. | The day the second dose is administered in accordance with the second column. | Indefinite after the start of the period. |
| | (3) One dose of the approved vaccine opposite. | 14th day after the dose is administered. | 270th day (including that day) after the day the dose is administered. |
| | (4) One dose of the approved vaccine opposite, followed by a dose of another approved vaccine, administered at least 86 days after the firstmentioned dose was administered. | The day the second dose is administered in accordance with the second column. | Indefinite after the start of the period. |
| | (5) Vaccination in accordance with paragraph (4), and where the doses are administered at a shorter interval than as specified in paragraph (4) and allowed by the Director. | The day the second dose is administered in accordance with the second column. | 270th day (including that day) after the day the first dose is administered plus a period fixed by the Director, being not more than 85 days and corresponding to the actual interval between the first and second doses. |
| 5. Sinopharm COVID-19 vaccine | (1) One dose of the approved vaccine opposite, administered to a Type T recovered | 14th day after the dose is administered in accordance with the second column. | 120th day (including that day) after the day the dose is administered. |

FIRST SCHEDULE — *continued*

| | | | |
|--|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| | individual at least 28 days after the relevant start date for the COVID-19 infection concerned. | | |
| | (2) One dose of the approved vaccine opposite, administered to a Type S recovered individual after his or her recovery from the COVID-19 infection. | 14th day after the dose is administered in accordance with the second column. | 120th day (including that day) after the day the dose is administered. |
| | (3) Two doses of the approved vaccine opposite, or a combination of defined approved vaccines, administered to a Type T recovered individual, the first dose of which is administered at least 28 days after the relevant start date for the COVID-19 infection concerned and the second dose at least 17 days after the firstmentioned dose was administered. | 14th day after the second dose is administered in accordance with the second column. | 270th day (including that day) after the day the second dose is administered. |
| | (4) Two doses of the approved vaccine opposite, or a combination of defined approved vaccines, administered to a Type S recovered | 14th day after the second dose is administered in accordance with the second column. | 270th day (including that day) after the day the second dose is administered. |

FIRST SCHEDULE — *continued*

| | | | |
|--|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| | individual after his or her recovery from the COVID-19 infection, where the respective doses are each administered at least 17 days apart. | | |
| | (5) One dose of the approved vaccine opposite and a second dose of another approved vaccine that is not a defined approved vaccine, administered to a Type T recovered individual, the first dose of which is administered at least 28 days after the relevant start date for the COVID-19 infection concerned and the second dose at least 17 days after the firstmentioned dose was administered. | 14th day after the second dose is administered in accordance with the second column. | 270th day (including that day) after the day the second dose is administered. |
| | (6) One dose of the approved vaccine opposite and a second dose of another approved vaccine that is not a defined approved vaccine, administered to a Type S recovered individual after | 14th day after the second dose is administered in accordance with the second column. | 270th day (including that day) after the day the second dose is administered. |

FIRST SCHEDULE — *continued*

| | | | |
|--|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| | his or her recovery from the COVID-19 infection, where the respective doses are each administered at least 17 days apart. | | |
| | (6A) Vaccination in accordance with paragraph (3), (4), (5) or (6), followed by another dose of any approved vaccine, administered at least 86 days after the day the second dose is administered. | The day the third dose is administered in accordance with the second column. | Indefinite after the start of the period. |
| | (7) Two doses of the approved vaccine opposite, administered at least 17 days apart. | 14th day after the second dose is administered in accordance with the second column. | 120th day (including that day) after the day the second dose is administered. |
| | (8) One dose of the approved vaccine opposite, followed by a dose of another approved vaccine, administered at least 17 days after the firstmentioned dose is administered. | 14th day after the second dose is administered in accordance with the second column. | 120th day (including that day) after the day the second dose is administered. |
| | (9) Three doses of the defined approved vaccine opposite, where each dose is administered at | The day the third dose is administered in accordance with the second column. | 270th day (including that day) after the day the third dose is administered. |

FIRST SCHEDULE — *continued*

| | | | |
|--|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| | least 17 days apart. | | |
| | (10) Two doses of the defined approved vaccine opposite followed by a third dose either of Sinovac-Coronavac COVID-19 vaccine or another approved vaccine that is not a defined approved vaccine, where each dose is administered at least 17 days apart. | The day the third dose is administered in accordance with the second column. | 270th day (including that day) after the day the third dose is administered. |
| | (11) One dose of the defined approved vaccine opposite, followed by a dose of another approved vaccine that is not a defined approved vaccine, followed by a third dose of a defined approved vaccine, where each dose is administered at least 17 days apart. | The day the third dose is administered in accordance with the second column. | 270th day (including that day) after the day the third dose is administered. |
| | (12) One dose of the defined approved vaccine opposite, followed by a dose of Sinovac-Coronavac COVID-19 vaccine, then followed by a third dose of any approved | The day the third dose is administered in accordance with the second column. | 270th day (including that day) after the day the third dose is administered. |

FIRST SCHEDULE — *continued*

| | | | |
|--|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | vaccine, where each dose is administered at least 17 days apart. | | |
| | (13) Vaccination as described in paragraph (9) followed by a fourth dose of any approved vaccine administered at least 86 days after the third dose is administered. | The day the fourth dose is administered in accordance with the second column. | Indefinite after the start of the period. |
| | (14) Vaccination as described in paragraph (10), (11) or (12) followed by a fourth dose of any approved vaccine administered at least 86 days after the third dose is administered. | The day the fourth dose is administered in accordance with the second column. | Indefinite after the start of the period. |
| | (15) At least 4 doses of approved vaccines, one of which is the approved vaccine opposite, and where the third and fourth doses are administered at a shorter interval than as specified in paragraph (13) or (14) and allowed by the Director. | The day the fourth dose is administered in accordance with the second column. | 270th day (including that day) after the start of the period in paragraph (9), (10), (11) or (12) (as the case may be) plus a period fixed by the Director, being not more than 85 days and corresponding to the actual interval between the third and fourth doses. |

FIRST SCHEDULE — *continued*

| | | | |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| 6. Sinovac-Coronavac COVID-19 vaccine | (1) One dose of the approved vaccine opposite, administered to a Type T recovered individual at least 28 days after the relevant start date for the COVID-19 infection concerned. | 14th day after the dose is administered in accordance with the second column. | 120th day (including that day) after the day the dose is administered. |
| | (2) One dose of the approved vaccine opposite, administered to a Type S recovered individual after his or her recovery from the COVID-19 infection. | 14th day after the dose is administered in accordance with the second column. | 120th day (including that day) after the day the dose is administered. |
| | (3) Two doses of the approved vaccine opposite, administered to a Type T recovered individual, the first dose of which is administered at least 28 days after the relevant start date for the COVID-19 infection concerned and the second dose at least 13 days after the firstmentioned dose was administered. | 14th day after the second dose is administered in accordance with the second column. | 270th day (including that day) after the day the second dose is administered. |
| | (4) One dose of the approved vaccine opposite and a dose of another defined approved vaccine, | 14th day after the second dose is administered in accordance with the second column. | 270th day (including that day) after the day the second dose is administered. |

FIRST SCHEDULE — *continued*

| | | | |
|--|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| | administered to a Type T recovered individual, the first dose of which is administered at least 28 days after the relevant start date for the COVID-19 infection concerned and the second dose at least 17 days after the firstmentioned dose was administered. | | |
| | (5) Two doses of the approved vaccine opposite, administered to a Type S recovered individual after his or her recovery from the COVID-19 infection, where the respective doses are each administered at least 13 days apart. | 14th day after the second dose is administered in accordance with the second column. | 270th day (including that day) after the day the second dose is administered. |
| | (6) One dose of the approved vaccine opposite and one dose of another defined approved vaccine, administered to a Type S recovered individual after his or her recovery from the COVID-19 infection, where the respective doses are each administered at | 14th day after the second dose is administered in accordance with the second column. | 270th day (including that day) after the day the second dose is administered. |

FIRST SCHEDULE — *continued*

| | | | |
|--|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| | least 17 days apart. | | |
| | (7) One dose of the approved vaccine opposite and a second dose of another approved vaccine that is not a defined approved vaccine, administered to a Type T recovered individual, the first dose of which is administered at least 28 days after the relevant start date for the COVID-19 infection concerned and the second dose at least 17 days after the firstmentioned dose was administered. | 14th day after the second dose is administered in accordance with the second column. | 270th day (including that day) after the day the second dose is administered. |
| | (8) One dose of the approved vaccine opposite and a second dose of another approved vaccine that is not a defined approved vaccine, administered to a Type S recovered individual after his or her recovery from the COVID-19 infection, where the respective doses are each administered at | 14th day after the second dose is administered in accordance with the second column. | 270th day (including that day) after the day the second dose is administered. |

FIRST SCHEDULE — *continued*

| | | | |
|--|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| | least 17 days apart. | | |
| | (8A) Vaccination in accordance with paragraph (3), (4), (5), (6), (7) or (8), followed by another dose of any approved vaccine, administered at least 86 days after the day the second dose is administered. | The day the third dose is administered in accordance with the second column. | Indefinite after the start of the period. |
| | (9) Two doses of the approved vaccine opposite, administered at least 13 days apart. | 14th day after the second dose is administered in accordance with the second column. | 120th day (including that day) after the day the second dose is administered. |
| | (10) One dose of the approved vaccine opposite, followed by a dose of another approved vaccine, administered at least 17 days after the firstmentioned dose is administered. | 14th day after the second dose is administered in accordance with the second column. | 120th day (including that day) after the day the second dose is administered. |
| | (11) Three doses of the defined approved vaccine opposite, where the first 2 doses are administered at least 13 days apart, and where the second and third doses are administered at least 17 days apart. | The day the third dose is administered in accordance with the second column. | 270th day (including that day) after the day the third dose is administered. |

FIRST SCHEDULE — *continued*

| | | | |
|--|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| | (12) Two doses of the defined approved vaccine opposite administered at least 13 days apart, followed by a third dose either of Sinopharm COVID-19 vaccine or another approved vaccine that is not a defined approved vaccine, where the second and third doses are administered at least 17 days apart. | The day the third dose is administered in accordance with the second column. | 270th day (including that day) after the day the third dose is administered. |
| | (13) One dose of the defined approved vaccine opposite, followed by a dose of another approved vaccine that is not a defined approved vaccine, followed by a third dose of a defined approved vaccine, where each dose is administered at least 17 days apart. | The day the third dose is administered in accordance with the second column. | 270th day (including that day) after the day the third dose is administered. |
| | (14) One dose of the defined approved vaccine opposite, followed by a dose of Sinopharm COVID-19 vaccine, followed by a third dose of any approved vaccine, where | The day the third dose is administered in accordance with the second column. | 270th day (including that day) after the day the third dose is administered. |

FIRST SCHEDULE — *continued*

| | | | |
|-----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | each dose is administered at least 17 days apart. | | |
| | (15) Vaccination as described in paragraph (11) followed by a fourth dose of any approved vaccine administered at least 86 days after the third dose is administered. | The day the fourth dose is administered in accordance with the second column. | Indefinite after the start of the period. |
| | (16) Vaccination as described in paragraph (12), (13) or (14) followed by a fourth dose of any approved vaccine administered at least 86 days after the third dose is administered. | The day the fourth dose is administered in accordance with the second column. | Indefinite after the start of the period. |
| | (17) At least 4 doses of approved vaccines, one of which is the approved vaccine opposite, and where the third and fourth doses are administered at a shorter interval than as specified in paragraph (15) or (16) and allowed by the Director. | The day the fourth dose is administered in accordance with the second column. | 270th day (including that day) after the start of the period in paragraph (11), (12), (13) or (14) (as the case may be) plus a period fixed by the Director, being not more than 85 days and corresponding to the actual interval between the third and fourth doses. |
| 7. Covaxin COVID-19 vaccine | (1) One dose of the approved vaccine opposite, | 14th day after the dose is administered in | 270th day (including that day) after the day |

FIRST SCHEDULE — *continued*

| | | | |
|--|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| | administered to a Type T recovered individual at least 28 days after the relevant start date for the COVID-19 infection concerned. | accordance with the second column. | the dose is administered. |
| | (2) One dose of the approved vaccine opposite, administered to a Type S recovered individual after his or her recovery from the COVID-19 infection. | 14th day after the dose is administered in accordance with the second column. | 270th day (including that day) after the day the dose is administered. |
| | (2A) Vaccination in accordance with paragraph (1) or (2), followed by another dose of any approved vaccine, administered at least 86 days after the day the first dose is administered. | The day the second dose is administered in accordance with the second column. | Indefinite after the start of the period. |
| | (3) Two doses of the approved vaccine opposite, administered at least 24 days apart. | 14th day after the second dose is administered in accordance with the second column. | 270th day (including that day) after the day the second dose is administered. |
| | (4) One dose of the approved vaccine opposite, followed by a dose of another approved vaccine that is not a defined approved vaccine, administered at least 24 days after the | 14th day after the second dose is administered in accordance with the second column. | 270th day (including that day) after the day the second dose is administered. |

FIRST SCHEDULE — *continued*

| | | | |
|--|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | firstmentioned dose is administered. | | |
| | (5) One dose of the approved vaccine opposite, followed by a dose of a defined approved vaccine, administered at least 17 days after the firstmentioned dose is administered. | 14th day after the second dose is administered in accordance with the second column. | 120th day (including that day) after the day the second dose is administered. |
| | (6) Two doses of the approved vaccine opposite or one dose thereof in combination with a dose of another approved vaccine, where the doses are administered at such other intervals as may be allowed by the Director. | 14th day after the second dose is administered in accordance with the second column. | The following day (including that day) after the day the second dose is administered: (a) 120th day where the second dose is a defined approved vaccine; (b) 270th day for any other approved vaccine. |
| | (7) Three doses of the approved vaccine opposite, where the first 2 doses are administered at least 24 days apart, and where the second and third doses are administered at least 86 days apart. | The day the third dose is administered in accordance with the second column. | Indefinite after the start of the period. |

FIRST SCHEDULE — *continued*

| | | | |
|--|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| | (8) Two doses of the approved vaccine opposite administered at least 24 days apart, followed by one dose of another approved vaccine administered at least 86 days after the second dose is administered. | The day the third dose is administered in accordance with the second column. | Indefinite after the start of the period. |
| | (9) One dose of the approved vaccine opposite, followed by 2 doses of another approved vaccine that is not a defined approved vaccine or a combination of approved vaccines none of which is a defined approved vaccine, where the first 2 doses are administered at least 17 days apart, and where the second and third doses are administered at least 86 days apart. | The day the third dose is administered in accordance with the second column. | Indefinite after the start of the period. |
| | (10) One dose of the approved vaccine opposite, followed by 2 doses of any defined approved vaccine or combination of defined approved vaccines, where the respective | The day the third dose is administered in accordance with the second column. | 270th day (including that day) after the day the third dose is administered. |

FIRST SCHEDULE — *continued*

| | | | |
|--|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|
| | doses are each administered at least 17 days apart. | | |
| | (11) Vaccination in accordance with paragraph (6) where the second dose is a defined approved vaccine, followed by another dose of any defined approved vaccine, where the second and third doses are administered at least 17 days apart. | The day the third dose is administered in accordance with the second column. | 270th day (including that day) after the day the third dose is administered. |
| | (12) Vaccination in accordance with paragraph (6) where the second dose is an approved vaccine that is not a defined approved vaccine, followed by a third dose of any approved vaccine that is not a defined approved vaccine, where the second and third doses are administered at least 86 days apart. | The day the third dose is administered in accordance with the second column. | Indefinite after the start of the period. |
| | (13) At least 3 doses of approved vaccines, one of which is the approved vaccine opposite, and where the second and third doses | The day the third dose is administered in accordance with the second column. | 270th day (including that day) after the day the second dose is administered plus a period fixed by the Director, being not more |

FIRST SCHEDULE — *continued*

| | | | |
|---------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | are administered at a shorter interval than as specified in paragraph (7), (8), (9) or (12) and allowed by the Director. | | than 85 days and corresponding to the actual interval between the second and third doses. |
| | (14) Vaccination in accordance with paragraph (10) followed by a fourth dose of any approved vaccine administered at least 86 days after the third dose is administered. | The day the fourth dose is administered in accordance with the second column. | Indefinite after the start of the period. |
| | (15) At least 4 doses where vaccination is in accordance with paragraph (10) for the first 3 doses and the fourth dose is any approved vaccine, and where the third and fourth doses are administered at a shorter interval than as specified in paragraph (14) and allowed by the Director. | The day the fourth dose is administered in accordance with the second column. | 270th day (including that day) after the day the third dose is administered plus a period fixed by the Director, being not more than 85 days and corresponding to the actual interval between the third and fourth doses. |
| 8. COVOVAX COVID-19 vaccine or Nuvaxovid (Novavax COVID-19 vaccine) | (1) One dose of the approved vaccine opposite, administered to a Type T recovered individual at least 28 days after the relevant start date for the COVID- | 14th day after the dose is administered in accordance with the second column. | 270th day (including that day) after the day the dose is administered. |

FIRST SCHEDULE — *continued*

| | | | |
|--|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| | 19 infection concerned. | | |
| | (2) One dose of the approved vaccine opposite, administered to a Type S recovered individual after his or her recovery from the COVID-19 infection. | 14th day after the dose is administered in accordance with the second column. | 270th day (including that day) after the day the dose is administered. |
| | (2A) Vaccination in accordance with paragraph (1) or (2), followed by another dose of any approved vaccine, administered at least 86 days after the day the first dose is administered. | The day the second dose is administered in accordance with the second column. | Indefinite after the start of the period. |
| | (3) Two doses of the approved vaccine opposite, administered at least 17 days apart. | 14th day after the second dose is administered in accordance with the second column. | 270th day (including that day) after the day the second dose is administered. |
| | (4) One dose of the approved vaccine opposite, followed by a dose of another approved vaccine that is not a defined approved vaccine, administered at least 17 days after the firstmentioned dose is administered. | 14th day after the second dose is administered in accordance with the second column. | 270th day (including that day) after the day the second dose is administered. |
| | (5) One dose of the approved vaccine | 14th day after the second dose is | 120th day (including that |

FIRST SCHEDULE — *continued*

| | | | |
|--|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | opposite, followed by a dose of a defined approved vaccine, administered at least 17 days after the firstmentioned dose is administered. | administered in accordance with the second column. | day) after the day the second dose is administered. |
| | (6) Two doses of the approved vaccine opposite or one dose thereof in combination with a dose of another approved vaccine, where the doses are administered at such other intervals as may be allowed by the Director. | 14th day after the second dose is administered in accordance with the second column. | The following day (including that day) after the day the second dose is administered: (a) 120th day where the second dose is a defined approved vaccine; (b) 270th day for any other approved vaccine. |
| | (7) Three doses of the approved vaccine opposite, where the first 2 doses are administered at least 17 days apart, and where the second and third doses are administered at least 86 days apart. | The day the third dose is administered in accordance with the second column. | Indefinite after the start of the period. |
| | (8) Two doses of the approved vaccine opposite administered at least 17 days apart, followed | The day the third dose is administered in accordance with the second column. | Indefinite after the start of the period. |

FIRST SCHEDULE — *continued*

| | | | |
|--|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| | by one dose of another approved vaccine administered at least 86 days after the second dose is administered. | | |
| | (9) One dose of the approved vaccine opposite, followed by 2 doses of another approved vaccine that is not a defined approved vaccine or a combination of approved vaccines none of which is a defined approved vaccine, where the first 2 doses are administered at least 17 days apart, and where the second and third doses are administered at least 86 days apart. | The day the third dose is administered in accordance with the second column. | Indefinite after the start of the period. |
| | (10) One dose of the approved vaccine opposite, followed by 2 doses of any defined approved vaccine or combination of defined approved vaccines, where the respective doses are each administered at least 17 days apart. | The day the third dose is administered in accordance with the second column. | 270th day (including that day) after the day the third dose is administered. |

FIRST SCHEDULE — *continued*

| | | | |
|--|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | (11) Vaccination in accordance with paragraph (6) where the second dose is a defined approved vaccine, followed by another dose of any defined approved vaccine, where the second and third doses are administered at least 17 days apart. | The day the third dose is administered in accordance with the second column. | 270th day (including that day) after the day the third dose is administered. |
| | (12) Vaccination in accordance with paragraph (6) where the second dose is an approved vaccine that is not a defined approved vaccine, followed by a third dose of any approved vaccine that is not a defined approved vaccine, where the second and third doses are administered at least 86 days apart. | The day the third dose is administered in accordance with the second column. | Indefinite after the start of the period. |
| | (13) At least 3 doses of approved vaccines, one of which is the approved vaccine opposite, and where the second and third doses are administered at a shorter interval than as specified in paragraph (7), | The day the third dose is administered in accordance with the second column. | 270th day (including that day) after the day the second dose is administered plus a period fixed by the Director, being not more than 85 days and corresponding to the actual interval between the |

FIRST SCHEDULE — *continued*

| | | | |
|----------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | (8), (9) or (12) and allowed by the Director. | | second and third doses. |
| | (14) Vaccination in accordance with paragraph (10) followed by a fourth dose of any approved vaccine administered at least 86 days after the third dose is administered. | The day the fourth dose is administered in accordance with the second column. | Indefinite after the start of the period. |
| | (15) At least 4 doses where vaccination is in accordance with paragraph (10) for the first 3 doses and the fourth dose is any approved vaccine, and where the third and fourth doses are administered at a shorter interval than as specified in paragraph (14) and allowed by the Director. | The day the fourth dose is administered in accordance with the second column. | 270th day (including that day) after the day the third dose is administered plus a period fixed by the Director, being not more than 85 days and corresponding to the actual interval between the third and fourth doses. |
| 9. Convidecia (CanSino Biologics COVID-19 vaccine) | (1) One dose of the approved vaccine opposite, administered to a Type T recovered individual at least 28 days after the relevant start date for the COVID-19 infection concerned. | 14th day after the dose is administered in accordance with the second column. | 270th day (including that day) after the day the dose is administered. |
| | (2) One dose of the approved vaccine opposite, | 14th day after the dose is administered in | 270th day (including that day) after the day |

FIRST SCHEDULE — *continued*

| | | | |
|--|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | administered to a Type S recovered individual after his or her recovery from the COVID-19 infection. | accordance with the second column. | the dose is administered. |
| | (3) Vaccination in accordance with paragraph (1) or (2), followed by another dose of any approved vaccine, administered at least 86 days after the day the first dose is administered. | The day the second dose is administered in accordance with the second column. | Indefinite after the start of the period. |
| | (4) One dose of the approved vaccine opposite. | 14th day after the dose is administered. | 270th day (including that day) after the day the dose is administered. |
| | (5) One dose of the approved vaccine opposite, followed by a dose of another approved vaccine, administered at least 86 days after the firstmentioned dose is administered. | The day the second dose is administered in accordance with the second column. | Indefinite after the start of the period. |
| | (6) Vaccination in accordance with paragraph (5), and where the doses are administered at a shorter interval than as specified in paragraph (5) and allowed by the Director. | The day the second dose is administered in accordance with the second column. | 270th day (including that day) after the day the first dose is administered plus a period fixed by the Director, being not more than 85 days and corresponding to the actual interval |

FIRST SCHEDULE — *continued*

| | | | |
|--|--|--|-------------------------------------|
| | | | between the first and second doses. |
|--|--|--|-------------------------------------|

[S 634/2022 wef 29/07/2022]

[S 445/2022 wef 01/06/2022]

[S 91/2022 wef 14/02/2022]

[S 796/2022 wef 10/10/2022]

SECOND SCHEDULE

[Deleted by S 796/2022 wef 10/10/2022]

Made on 23 April 2021.

NG HOW YUE
*Permanent Secretary
 (Health Development),
 Ministry of Health,
 Singapore.*

[AG/LEGIS/SL/137/2020/13 Vol. 1]